EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

How do we manage hyperhemolysis syndrome

Brian D Adkins iD, Samer Z Kaylani, Alecia Nero, Ibrahim F Ibrahim, Yu-Min Shen, Ravindra Sarode

Transfusion · 2024-10 · 64 (10) · 1822-1829

DOI: 10.1111/trf.17995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 03.10.2024. Verfasst von Brian D Adkins und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Hemolysis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperhemolysis syndrome (HHS) is a catastrophic anemia characterized by destruction of both donor and patient red blood cells (RBC). HHS occurs after transfusion and can cause significant morbidity and mortality. Given the difficulty in diagnosing and managing this process, we provide a detailed overview of our treatment protocol. Study Design and Methods Members of the Transfusion Medicine and Hematology faculty at our institution collaborated in an iterative process to produce a consensus approach to patients with HHS.

Results

We present diagnostic criteria for HHS: recent transfusion within past 7 days (up to 21 days), rapid hemoglobin decline to below the pretransfusion level (usually hemoglobin drop >25% from pretransfusion), a significant decrease in HbA% (in patients with sickle cell disease or beta thalassemia), low or decreasing reticulocyte count in a patient with worsening anemia, and laboratory evidence of hemolysis. We also describe an in‐depth approach to management focusing on optimizing hematopoiesis while dampening the immune response.

Conclusion

We provide a comprehensive approach to the diagnosis and management of HHS based on contemporary literature and clinical experience designed to optimize outcomes for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, HemolyticHemolysisHumansSyndromeTransfusion Reaction

Stichwörter der Autor:innen

RBC transfusionhematology – red cellstransfusion complications‐non infectious

Autor:innen und Institutionen

  • Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Children's Health System, Dallas, Texas, USA.
  • Division of Hematology and Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

ORCID-Profile: Brian D Adkins

Zitieren

APA

Adkins, B. D., Kaylani, S. Z., Nero, A., Ibrahim, I. F., Shen, Y. M., & Sarode, R. (2024). How do we manage hyperhemolysis syndrome. Transfusion, 64(10), 1822-1829. https://doi.org/10.1111/trf.17995

Vancouver

Adkins BD, Kaylani SZ, Nero A, Ibrahim IF, Shen YM, Sarode R. How do we manage hyperhemolysis syndrome. Transfusion. 2024;64(10):1822-1829. doi:10.1111/trf.17995

BibTeX
@article{Adkins2024,
  author = {Adkins, Brian D and Kaylani, Samer Z and Nero, Alecia and Ibrahim, Ibrahim F and Shen, Yu-Min and Sarode, Ravindra},
  title = {How do we manage hyperhemolysis syndrome},
  journal = {Transfusion},
  year = {2024},
  volume = {64},
  number = {10},
  pages = {1822--1829},
  doi = {10.1111/trf.17995}
}
Kostenlos starten →